Serologic efficacy of a two dose measles vaccination schedule at 6 and 11 months of age: a prospective study

• Autor(a) principal: Pannuti, Claudio S.
• Data de Publicação: 1990
• Outros Autores: Souza, Vanda A. U. F. de, Sato, Helena K., Fink, Maria C. D. S., Ribeiro, Mirian I., Hisi, Sumie K., Castelo, Adauto, Mendonça, João S. de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista do Instituto de Medicina Tropical de São Paulo
• Texto Completo: https://www.revistas.usp.br/rimtsp/article/view/28777
• topic: Sarampo; Vacinação

A prospective study was designed to evaluate the serologic efficacy of a two dose meas les vaccination schedule, at 6 months and 11 months of age. Infants were given a further attenuated measles virus vaccine (BIKEN CAM 70, Fundação Oswaldo Cruz) and serum samples were tested for measles antibodies using the indirect immunofluorescence technique (IFA) and ELISA. Seroconversion rates 6 to 12 months (mean of 8.0 ±1.7 months) following the second dose of measles vaccine were 88.5% (85/96) by IFA and 96.8% (93/96) by ELISA. No measles cases were reported during the study period. In regions where a significant proportion of measles cases occurs before nine months of age, vaccination with a two doses schedule, at 6 and 11 months of age, may represent an alternative for measles control.